Astec LifeSciences Limited has submitted a formal response to BSE Limited regarding an inquiry about significant increases in trading volume of the company's securities across exchanges in the recent past. The communication is in reference to BSE's email Ref. No. L/SURV/ONL/PV/SJ/2026-2027/4238 dated 10th September, 2026.
The company confirms its awareness of its responsibility as a listed entity to disseminate information that could impact share prices. They state they have been promptly disclosing events or information required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Specifically, Astec LifeSciences confirms:
- Full compliance with disclosure requirements under the Listing Regulations
- No developments requiring mandatory disclosure under Listing Regulations have occurred
- No developments requiring disclosure under SEBI (Prohibition of Insider Trading) Regulations, 2015 have occurred
The company affirms its commitment to continue fully complying with obligations under both the Listing Regulations and PIT Regulations, making appropriate disclosures as mandated when required.
The response was digitally signed by Tejashree Rohan Pradhan, Company Secretary & Compliance Officer (FCS 7167), on 11th September, 2026 at 09:21:12 IST.
Financial Impact
No financial impact or quantitative figures are disclosed in this regulatory compliance communication.